News

Stimulating Interactions

NEWS

GraphWear presented SweatSmart beta at the NASDAQ

GraphWear presented SweatSmart beta at the NASDAQ GraphWear presented SweatSmart beta at the NASDAQ bell closing ceremony along with the CEO of the 49ers, Jed York and were featured on Times Square. This is the first time in human history that players would be able to extract their health information in real-time without blood pricks and they are excited to […]

Read more

OneSkin closes $2M Financing to reverse aging skin

OneSkin closes $2M Financing to reverse aging skin OneSkin Technologies is working on optimizing their technology of in vitro tissue aging and quantitative measurement of anti-aging molecule effects over the age of skin models. This platform will allow them to screen for molecules that molecules that truly rejuvenate skin or prevent aging.

Read more

New Core Equipment: GE WAVE 25

New Core Equipment: GE WAVE 25 The WAVE 25 bioreactor system will allow QB3@953 startups to reliably and repeatedly grow up to 25L of cells for protein production. The single use bags standardize production and eliminates the need for clean-rooms, all of which saves time and money. We are dedicated to helping our researchers get reliable data fast – and […]

Read more

QB3@953 Companies Attract $1.36B In Capital

QB3@953 Companies Attract $1.36B In Capital San Francisco, CA, May 1, 2017 – QB3@953 proved definitively that its incubator facilities allow life science startups to progress at lightening speed, making a huge impact on the life-science ecosystem of the Bay Area. QB3@953 tenant and alumni companies are thriving. In the three short years since its founding, QB3@953 companies attracted $1.36Bn […]

Read more

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne

Naked Biome closes $5M Series Seed Financing for microbiome treatment of acne Led by dermatologist Dr. Emma Taylor, the Naked Biome team is developing microbiome-based acne therapeutics. They have now closed a $5 million seed round to get them through clinical proof-of-principle.

Read more

David Seftel featured in San Francisco Chronicle

David Seftel featured in San Francisco Chronicle One of the great aspects of our community, are the wonderful people we work with.  Reading the front page of the Chronicle recently, we discovered that Dr. David Seftel is not only a co-founder of Enable Biosciences, but he also has a storied past of resisting Apartheid in South Africa and then becoming the […]

Read more

Celgene acquires Delinia

Celgene acquires Delinia Three weeks after their graduation party, Delinia announced they had been acquired by Celgene for $300M upfront and up to $475M in milestones. Delinia’s co-founder and CSO, Jeff Greve, began with a single bench at QB3@953 in 2014. Less than two years later, he has delivered an exciting autoimmune candidate to Celgene – now that’s awesome!  

Read more

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company Telo Therapeutics enters into an Oncology-focused research collaboration with GSK San Francisco, CA, Feb 2, 2017 – QB3@953, the Bay Area’s premier life science incubator, today announced the collaboration between one of its member companies, Telo Therapeutics, and one of its sponsor companies, GlaxoSmithKline (GSK). Telo Therapeutics […]

Read more

Servier partners with QB3@953 to find and cultivate innovative startups

Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology. This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to […]

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more
Page 1 of 712345...Last »

Address

953 Indiana St.
San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter